Dianthus Therapeutics’ (DNTH) “Buy” Rating Reiterated at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 71.09% from the stock’s previous close.

Several other analysts also recently issued reports on the company. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating on the stock. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and a consensus target price of $46.83.

Dianthus Therapeutics Trading Down 3.9 %

Shares of DNTH stock opened at $23.38 on Wednesday. The stock has a market capitalization of $691.98 million, a P/E ratio of -9.35 and a beta of 1.82. The firm’s 50 day moving average is $22.65 and its 200 day moving average is $24.97. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. MetLife Investment Management LLC increased its holdings in shares of Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after acquiring an additional 433 shares in the last quarter. Invesco Ltd. lifted its position in Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock valued at $251,000 after purchasing an additional 790 shares during the period. SG Americas Securities LLC grew its position in Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after purchasing an additional 814 shares during the period. Barclays PLC raised its stake in shares of Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock valued at $933,000 after buying an additional 1,082 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Dianthus Therapeutics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock valued at $3,641,000 after buying an additional 1,092 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.